Altered expression of histone deacetylases in cancer

Critical Reviews in Oncogenesis
Diana MontezumaCarmen Jerónimo

Abstract

Epigenetic mechanisms, including histone deacetylation, are commonly deregulated in cancer. Histone deacetylases (HDACs) play an important role in tumorigenesis and their value as therapeutic targets has been under intense investigation in recent years. In addition to classical HDACs (HDAC classes I, II, and IV), sirtuins (class III HDACs) are currently in the spotlight of cancer research showing promise as cancer biomarkers and therapeutic targets. Translating research knowledge into the clinical setting is, however, a challenging and demanding task. This review describes the association between HDAC deregulation and cancer promotion and highlights recent advances in the use of HDAC inhibitors in the management of neoplastic diseases, with emphasis on urological tumors. Sirtuins' bivalent role in tumor development and therapeutic agents targeting these molecules will be also addressed.

Citations

Sep 3, 2016·Epigenomics·Wallax Augusto Silva FerreiraBárbara do Nascimento Borges
Aug 2, 2018·Clinical Epigenetics·Aline KaletschGünter Niegisch
Feb 14, 2020·Cancers·Sara S OltraMaría Teresa Martinez
Feb 6, 2020·Aging·Melchiorre CervelloJames A McCubrey
Dec 4, 2020·Journal of Experimental & Clinical Cancer Research : CR·Xue-Ting HuXiang Xu
Jan 17, 2016·Molecular Cancer Therapeutics·Maria PinkerneilGuenter Niegisch

❮ Previous
Next ❯

Related Concepts

Related Feeds

Cancer Epigenetics (Keystone)

Epigenetic changes are present and dysregulated in many cancers, including DNA methylation, non-coding RNA segments and post-translational protein modifications. The epigenetic changes may or may not provide advantages for the cancer cells. Here is the latest research on cancer epigenetics.

Cancer Epigenetics

Epigenetic changes are present and dysregulated in many cancers, including DNA methylation, non-coding RNA segments and post-translational protein modifications. The epigenetic changes may or may not provide advantages for the cancer cells. Here is the latest research on cancer epigenetics.

Cancer Epigenetics & Methyl-CpG (Keystone)

Epigenetic changes are present and dysregulated in many cancers, including DNA methylation, non-coding RNA segments and post-translational protein modifications. Here is the latest research on cancer epigenetics and methyl-CpG binding proteins including ZBTB38.

Cancer Epigenetics and Senescence (Keystone)

Epigenetic changes are present and dysregulated in many cancers, including DNA methylation, non-coding RNA segments and post-translational protein modifications. The epigenetic changes may be involved in regulating senescence in cancer cells. This feed captures the latest research on cancer epigenetics and senescence.

Cancer Epigenetics & Metabolism (Keystone)

Epigenetic changes are present and dysregulated in many cancers, including DNA methylation, non-coding RNA segments and post-translational protein modifications. The epigenetic changes may or may not provide advantages for the cancer cells. This feed focuses on the relationship between cell metabolism, epigenetics and tumor differentiation.

Cell Signaling & Cancer Epigenetics (Keystone)

Epigenetic changes are present and dysregulated in many cancers, including DNA methylation, non-coding RNA segments and post-translational protein modifications. This feed covers the latest research on signaling and epigenetics in cell growth and cancer.

Related Papers

The Journal of Clinical Investigation
Alison C West, Ricky W Johnstone
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research
David S Schrump
© 2022 Meta ULC. All rights reserved